Source: WESTLAKE VILLAGE, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s first-in-human, Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of psoriasis and the associated pruritus, or itch. SNA-125 is…...

Source: LinkedIn QFR Solutions has earned another Top spot in LinkedIn’s Top 25 Most Socially Engaged Staffing Agencies. This is the second top spot for QFR Solutions since the inception of the awards in 2016. QFR ranked #2 in 2017 and #1 in 2016. There were nearly 30,000 firms considered…...